PCM
CRVS icon

Prelude Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Prelude Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,027
Closed -$31.9K – 1061
2025
Q1 		$31.9K Buy
+10,027
New +$47.2K ﹤0.01% 1113
2018
Q3 		– Sell
-939
Closed -$10K – 1768
2018
Q2 		$10K Buy
+939
New +$10.5K ﹤0.01% 1485
2017
Q2 		– Sell
-14,852
Closed -$308K – 1636
2017
Q1 		$308K Buy
14,852
+5,450
+58% +$85.4K 0.03% 424
2016
Q4 		$134K Buy
+9,402
New +$143K 0.02% 733

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's CRVS Position: Q2 2025 in Review

Prelude Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 10,027 shares — an estimated $31.9K sold.

Prelude Capital Management first reported a position in CRVS in Q4 2016 and held it in 4 quarters. The position peaked at $308K in Q1 2017. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Prelude Capital Management reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 10,027 Corvus Pharmaceuticals shares in Q2 2025, an estimated $31.9K.
  • Prelude Capital Management first reported a position in Corvus Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Prelude Capital Management's Corvus Pharmaceuticals position peaked at $308K in Q1 2017.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.